Literature DB >> 21300041

Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats.

Kuan-Hsing Chen1, Cheng-Chieh Hung, Hsiang-Hao Hsu, Yu-Hong Jing, Chih-Wei Yang, Jan-Kan Chen.   

Abstract

Diabetic nephropathy (DN) is the major cause of end-stage renal disease. The early changes in DN are characterized by an increased in kidney size, glomerular volume, and kidney function, followed by the accumulation of glomerular extracellular matrix, increased urinary albumin excretion (UAE), glomerular sclerosis, and tubular fibrosis. Resveratrol (RSV) has been shown to ameliorate hyperglycemia and hyperlipidemia in streptozotocin-induced diabetic rats. In the present study, we examined the beneficial effects of RSV on DN and explored the possible mechanism of RSV action. Male Sprague-Dawley rats were injected with streptozotocin at 65mg/kg body weight. The induction of diabetes mellitus (DM) was confirmed by a fasting plasma glucose level ≥300mg/dL and symptoms of polyphagia and polydipsia. The DM rats were treated with or without RSV at 0.75mg/kg body weight 3 times a day for 8 weeks. Animals were sacrificed and kidney histology was examined by microscopy. Urinary albumin excretion, glomerular hypertrophy and expressions of fibronectin, collagen IV, and TGF-β in the glomeruli were alleviated in RSV-treated DM rats, but not in untreated DM rats. In addition, RSV treatment reduced the thickness of the glomerular basement membrane (GBM) to the original thickness and increased nephrin expressions to normal levels in DM rats. Moreover, RSV inhibited phosphorylation of smad2, smad3 and ERK1/2 in diabetic rat kidneys. This is the first report showing that RSV alleviates early glomerulosclerosis in DN through TGF-β/smad and ERK1/2 inhibition. In addition, podocyte injuries of diabetic kidneys are lessened by RSV. 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300041     DOI: 10.1016/j.cbi.2011.01.033

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  32 in total

1.  Modulating effect of SIRT1 activation induced by resveratrol on Foxo1-associated apoptotic signalling in senescent heart.

Authors:  Thomas K Sin; Angus P Yu; Benjamin Y Yung; Shea Ping Yip; Lawrence W Chan; Cesar S Wong; Michael Ying; John A Rudd; Parco M Siu
Journal:  J Physiol       Date:  2014-03-17       Impact factor: 5.182

2.  Estrogen receptor subtype ratio change protects against podocyte damage.

Authors:  Paola Catanuto; Xiaomei Xia; Simone Pereira-Simon; Sharon Elliot
Journal:  Curr Trends Endocinol       Date:  2017

3.  The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats.

Authors:  Sang Hoon Kim; Young Woo Jang; Patrick Hwang; Hyun Jung Kim; Gi Yeon Han; Chan Wha Kim
Journal:  Exp Mol Med       Date:  2012-01-31       Impact factor: 8.718

4.  Caveolin-1 deficiency protects against mesangial matrix expansion in a mouse model of type 1 diabetic nephropathy.

Authors:  T H Guan; G Chen; B Gao; M R Janssen; L Uttarwar; A J Ingram; J C Krepinsky
Journal:  Diabetologia       Date:  2013-06-21       Impact factor: 10.122

5.  Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in kidneys via proliferation-related signalling pathways.

Authors:  Xing Zhang; Hong Lu; Shuangshuang Xie; Cunzao Wu; Yangyang Guo; Yanyi Xiao; Shizhang Zheng; Hengyue Zhu; Yan Zhang; Yongheng Bai
Journal:  Br J Pharmacol       Date:  2019-11-28       Impact factor: 8.739

Review 6.  Resveratrol for the Management of Diabetes and its Downstream Pathologies.

Authors:  Moola Joghee Nanjan; James Betz
Journal:  Eur Endocrinol       Date:  2014-02-28

Review 7.  The metabolic syndrome and chronic kidney disease.

Authors:  Xin Zhang; Lilach O Lerman
Journal:  Transl Res       Date:  2016-12-09       Impact factor: 7.012

8.  [Screening active ingredients of Shenkangwan that regulate endothelial-mesenchymal transition of endothelial cells in vitro].

Authors:  Cha Zhang; Jia-Xing Zhang; Yi-Fan Xiong; Lu Lu; Ming-Qing Wang; Si-Ming Liu; Wei Xiao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-03-20

9.  Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats.

Authors:  Marta Llarena; Fernando Andrade; Mounia Hasnaoui; María P Portillo; Patricia Pérez-Matute; Jose M Arbones-Mainar; Elizabeth Hijona; María Jesús Villanueva-Millán; Leixuri Aguirre; Christian Carpéné; Luis Aldámiz-Echevarría
Journal:  J Physiol Biochem       Date:  2015-12-10       Impact factor: 4.158

Review 10.  Renoprotective effects of estrogen on acute kidney injury: the role of SIRT1.

Authors:  Fatemeh Darvishzadeh Mahani; Mohammad Khaksari; Alireza Raji-Amirhasani
Journal:  Int Urol Nephrol       Date:  2021-01-17       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.